|
|
||||||||




,¶
* Center for Vascular and Inflammatory Diseases and Departments of Surgery and Physiology, University of Maryland School of Medicine, Baltimore, MD 21201;
Department of Pathology, Duke University Medical Center, Durham, NC 27710;
Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556;
Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697; and
¶ Department of Microbiology and Immunology, Indiana University School of Medicine, South Bend, IN 46617
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
C1q deficiency in humans leads to enhanced susceptibility to infection and development of lupus-like autoimmune disease with essentially complete penetrance (8). In mice, genetic deficiencies of C1q result in impaired handling of immune complexes and heightened susceptibility to bacterial infection and autoimmunity (9, 10, 11). Recent reports demonstrate the importance of microenvironment and tissue specificity for bridging molecules, such as defense collagens, that link apoptotic cells to phagocytes. For example, C1q deficiency in mice leads to an accumulation of apoptotic bodies in the kidney and resultant glomerulonephritis in 25% of animals (12). These data are consistent with the hypothesis that C1q deficiency, resulting in inefficient clearance of apoptotic cells, leads to the release of intracellular components, exposure of the immune system to self-Ags, and subsequent autoimmunity. In addition, murine deficiency of the defense collagen mannose-binding lectin leads to inefficient clearance of apoptotic cells when apoptotic cells are injected intraperitoneally; however, the mutation is not associated with spontaneous autoimmunity (13). Efforts to elucidate mechanisms involving defense collagen-triggered clearance of apoptotic cells have thus far focused largely on identification of the receptor complex involved in regulating phagocytosis.
CD93, a transmembrane glycoprotein expressed on myeloid cells, endothelial cells, and platelets, was originally isolated and cloned based on its ability to modulate the C1q-triggered enhancement of the ingestion of target particles suboptimally opsonized with IgG or complement (14, 15, 16). However, further studies by Norsworthy et al. demonstrated that, while the CD93-deficient mouse was deficient in the in vivo clearance of apoptotic cells, the mechanism governing the clearance defect remained elusive; in vitro analysis of CD93-deficient macrophages demonstrated that these macrophages respond to immobilized C1q with an enhancement of the phagocytosis of IgG-opsonized particles and also preferentially engulf apoptotic cells in the presence of C1q-containing serum over apoptotic cells incubated in C1q-deficient serum (17). These studies prompted further investigation to identify the receptor or receptor complex responsible for the C1q-triggered enhancement of phagocytosis.
It has been suggested that another receptor, the low density lipoprotein receptor-related protein 1 (LRP3 or CD91), mediates the ingestion of apoptotic cells by forming a phagocyte receptor complex with calreticulin (CRT) and binding to C1q on apoptotic cells or, alternatively, by binding to CRT alone present on apoptotic cells and mediating their phagocytosis (6, 7, 18, 19). LRP is a large cell surface receptor that mediates endocytosis of numerous ligands, including apolipoprotein E-enriched lipoproteins, protease inhibitor complexes, and matrix proteins (reviewed in Ref. 20). Although direct genetic experiments have yet to confirm that LRP is capable of participating in phagocytosis, the LRP cytoplasmic domain associates with GULP (21), an adaptor protein known to participate in phagocytosis, and experiments using hybrid receptors revealed that the LRP cytoplasmic domain has sufficient information to trigger phagocytosis (22). Together, these data reveal the potential of LRP to mediate phagocytosis.
Collectively, these studies prompted us to test the hypotheses that LRP can mediate phagocytosis and that LRP is the receptor responsible for C1q-mediated enhancement of phagocytosis. To test these hypotheses, thioglycollate-elicited peritoneal macrophages or bone marrow-derived macrophages (BMDM) from mice generated using a tissue-specific loxP/Cre recombination strategy, that were either genetically deficient in or normally expressing LRP, were used to explore the role of LRP in the phagocytosis of ligand-coated microspheres and in the C1q-triggered enhancement of ingestion of a variety of physiologically important targets, including complement- and Ab-opsonized targets and apoptotic cells. The data demonstrate that, while LRP contributes to the phagocytosis of ligand-coated particles, it is not required for the C1q-triggered enhancement of phagocytosis, directly implying that other, still unidentified, receptor(s) exist to mediate this important innate immune function.
| Materials and Methods |
|---|
|
|
|---|
The human Jurkat T cell clone A3 was obtained from American Type Culture Collection. Alexa Fluor 633 and 546 labeling kits, RPMI 1640, penicillin/streptomycin, DMEM, trypsin-EDTA, and CFSE were purchased from Invitrogen. CFSE was reconstituted to 5 mM in DMSO and stored at –20°C. FBS was purchased from HyClone. Brewer-modified thioglycollate broth was obtained from BD Biosciences. Complete protease inhibitor tablets were purchased from Roche Diagnostics. ECL reagents were from Pierce. Versene was obtained from Lonza. Recombinant GST and GST-receptor-associated protein (RAP) were purified as described (23). Anti-tubulin Ab, anti-GST Ab, and etoposide were from Sigma-Aldrich. Etoposide was reconstituted at 10 mM in DMSO and stored at –20°C. Fluoresbrite Yellow Green carboxylate microspheres (1 µm) were purchased from Polysciences. Annexin V Ab was from BioVision. Anti-CD11b Ab was obtained from eBioscience. Human C1q was purified from human plasma by the method of Tenner et al. (24). Mouse C1q was isolated from mouse serum by ion exchange chromatography. Mouse serum was adjusted to 25 mM EDTA and passed over a column of Biorex70 resin (Bio-Rad) of equal volume that had been pre-equilibrated into 50 mM Tris (pH 7.4), 82 mM NaCl, and 25 mM EDTA. C1q was eluted with a salt gradient to 300 mM NaCl. Fractions containing functional C1q, as assessed by hemolytic titer, were pooled and concentrated by ultrafiltration (Amicon-Millipore). Serum completely lacking C1q was obtained from C1q-deficient mice (12).
Mice
Mice deficient in macrophage LRP were generated using loxP/Cre-mediated recombination essentially as described by Hu et al. (25), except that the mice were maintained on a low density lipoprotein receptor-deficient background for use in atherosclerosis studies to be reported elsewhere (A. P. Lillis, M. C. Greenlee, I. Mikhailenko, S. V. Pizzo, A. J. Tenner, D. K. Strickland, S. S. Bohlson, manuscript in preparation). Briefly, loxP-flanked LRP transgenic mice and mice expressing Cre recombinase driven by the lysozyme M promoter were used in a breeding scheme that ultimately generated experimental litters with all mice expressing loxP sites on both alleles of LRP. Litters were evenly divided with half of the siblings carrying one copy of Cre recombinase under the lysozyme M promoter, which led to recombination and deletion of LRP in macrophages (macLRP–/– mice). The other half of the siblings carried no copies of Cre and, therefore, expressed LRP normally in all tissues (LRP+/+ mice). All studies were reviewed and approved by the Institutional Animal Care and Use Committee (Indiana University School of Medicine, South Bend, IN, University of CA, Irvine, CA, and University of Maryland School of Medicine Baltimore, MD).
Cell culture
The human Jurkat T cell clone A3 was maintained in RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, and 10 mM HEPES (pH 7.4) at 5% CO2. Peritoneal macrophages were harvested from macLRP–/– and sibling control LRP+/+ mice 4 days after i.p. injection of 1 ml of 5% (w/v) Brewer-modified thioglycollate broth by flushing the peritoneum three times with 5 ml of ice-cold PBS. Macrophages were washed with ice-cold PBS and incubated in DMEM supplemented with 10% FBS and penicillin/streptomycin, in 6-well cell culture plates at 37°C in 10% CO2 for 3 days. BMDM were generated as described (26). Briefly, femurs, tibias, and humeri were isolated and shipped insulated overnight in BMDM medium (DMEM with 10% FBS, 15% L929 conditioned medium, penicillin/streptomycin, and 10 mM HEPES). Bones were flushed with DMEM supplemented with 2% FBS; RBC were lysed, and resident fibroblasts and macrophages were depleted by a preadhesion step for 2–4 h at 37°C in 5% CO2. Following maturation for four days, 6 ml of fresh medium was added and cells were considered fully mature at 7 days. Media was replenished every 2 or 3 days to maintain cell viability beyond day 7.
Western blotting
Thioglycollate-elicited peritoneal macrophages were lysed in a 50 mM Tris-HCl buffer (pH 7.4) containing 1% Nonidet P-40, 150 mM NaCl, and 1 mM EDTA and supplemented with complete protease inhibitor tablets to give final concentrations of 1 mM PMSF and 1 µg/ml each aprotinin, leupeptin, and pepstatin. Thirty micrograms of protein was resolved under nonreducing conditions by 4–12% Tris-glycine SDS-PAGE. Proteins were transferred to nitrocellulose at 30 volts overnight at 4°C and membrane was blocked with 3% milk in Tris-buffered saline (150 mM NaCl and 20 mM Tris (pH 7.4)) for 1 h. LRP was detected by incubation for 1 h at room temperature with 1 µg/ml rabbit polyclonal anti-LRP Ab 2629 (27). Membranes were washed, incubated with HRP-conjugated goat-anti-rabbit secondary Ab (1/3,000), and then washed and developed with ECL reagents. The LRP blot was stripped and reprobed with 1 µg/ml rabbit polyclonal anti-Mac-1 Ab, ARC-22 (a gift from L. Zhang, University of Maryland, Baltimore, MD) and with 1 µg/ml anti-tubulin Ab to confirm equivalent protein loading.
Soluble ligand and microbead uptake assays
Soluble GST-RAP was labeled with Alexa Fluor 633 according to the manufacturers instructions. Peritoneal macrophages, isolated as described above, were incubated with 5 nM Alexa Fluor 633-labeled GST-RAP in DMEM supplemented with 10% FBS and penicillin/streptomycin at 37°C for 30 min, washed twice in ice cold PBS, detached from the plate with trypsin-EDTA, and analyzed by flow cytometry. The number of cells staining positive for Alexa Fluor 633 was expressed as a percentage of total propidium iodide-negative (live) cells in each group. For protein-coated microbead uptake assays, green fluorescent microbeads (1 µm) were incubated with 3 mg/ml GST or GST-RAP for 1 h with periodic shaking. Beads were washed three times in PBS. Plated peritoneal macrophages were incubated with 25 beads/cell in DMEM supplemented with 10% FBS for 30 min, washed, removed from the plate with trypsin-EDTA, and analyzed by FACS. This procedure assumes that the fluorescence associated with the cells represents internalized beads. The percentage of cells with fluorescence greater than that of cells incubated without beads is expressed as the percentage of phagocytosis. The phagocytic index was determined by multiplying the percentage of phagocytosis by the mean fluorescence. For fluorescent microscopy, cells were plated on 0.1% gelatin-coated glass coverslips, incubated with beads that had been coated with GST, GST-RAP, or GST-heparin-binding domain (HBD) as described above, fixed, immunostained, and visualized using a Radiance2000 confocal laser-scanning microscope (Bio-Rad/Zeiss). Cell-associated beads were counted by optical sectioning through cell bodies of several random fields of cells.
To differentiate between beads that were completely engulfed and beads that were cell associated but not engulfed, four-channel fluorescent microscopy was used. LRP-expressing cells were labeled by preloading the cells with Alexa Fluor 647-conjugated RAP. Following a wash step to remove noninternalized RAP, Fluoresbrite Yellow Green beads conjugated to the specific protein (GST, GST-RAP, or GST-HBD) were incubated with cells for 60 min and then the cells were washed and fixed. Cells were then stained with anti-GST followed by goat anti-mouse Alexa Fluor 568. GST on the surface of the beads is recognized only if the beads are not fully engulfed. Phase images were used to identify LRP-null cells.
Opsonized erythrocyte and apoptotic cell phagocytosis assays
Phagocytosis assays using sheep erythrocytes opsonized with IgG (EAIgG) and sheep erythrocytes opsonized with complement component C4b (EAIgMC4b) were performed as described previously (28) with the following modification. BMDM were switched to DMEM supplemented with 10% FBS, penicillin/streptomycin, and 10 mM HEPES without L929 conditioned culture medium for 24 h before performing the assays. Cells were harvested from non-tissue culture-treated plastic petri dishes with Versene (0.2 mg/ml EDTA), washed three times in phagocytosis buffer (RPMI 1640 containing 2 mM L-glutamine, penicillin/streptomycin, and 5 mM MgCl2) and resuspended in phagocytosis buffer at 1.25 x 105/ml. Macrophages were added to wells previously coated with 4 or 8 µg/ml either C1q or human serum albumin (used as a control protein), allowed to adhere for 30 min at 37°C, and then incubated with targets for an additional 30 min. For phagocytosis of apoptotic cells, Jurkat cells were labeled with 5 µM CFSE for 30 min at 37°C and, following two washes, resuspended at 5 x 105/ml in complete medium with 40 µM etoposide and cultured for 12–18 h. Apoptosis was verified by annexin V/propidium iodide staining. BMDM were harvested and washed as described above, and 5 x 105 macrophages were incubated with 1.5 x 106 apoptotic cells for 15–60 min at 37°C. Nonadherent cells were removed by washing with PBS, and macrophages were harvested with trypsin-EDTA. Macrophages were stained with anti-CD11b and detected by flow cytometry. Macrophages that had engulfed apoptotic cells were calculated as follows: (CD11b and CFSE double-positive cells/total number of CD11b-positive cells) x 100. The 30-min time point has been previously reported in the literature and was also found to be an optimum point to observe the C1q-triggered enhancement of phagocytosis of Ab- and complement-tagged particles in the studies performed here (28, 29, 30). In addition, the 30-min time point consistently provided reproducible differences between the uptake of live and apoptotic cells.
Statistical analysis
Where indicated, comparison of means was performed using Students t test.
| Results |
|---|
|
|
|---|
Macrophage-specific, LRP-deficient mice were generated using loxP/Cre-mediated recombination as described in Materials and Methods. To evaluate the level of macrophage LRP expression, we examined both thioglycollate-elicited peritoneal macrophages and BMDM from macLRP–/– mice and LRP+/+ siblings. LRP deletion in peritoneal macrophages from LRP-deficient mice was confirmed by immunoblotting for LRP from macrophage extracts (Fig. 1A). Equivalent protein loading between macLRP–/– and LRP+/+ macrophage extracts was confirmed by blotting tubulin and the macrophage marker Mac-1 (CD11b/CD18).
|
BMDM were also examined for LRP expression by flow cytometry. Surface staining for LRP showed deletion of LRP in BMDM from macLRP–/– mice (Fig. 2, A and B), while staining for CD11b (a well-characterized macrophage marker) was unchanged between groups (Fig. 2, C and D). Multiple preparations of BMDM yielded consistently diminished levels of LRP on mac-LRP–/– macrophages compared with sibling controls (Fig. 2E). The highest number of LRP-positive macrophages detected in a macLRP–/– preparation was 64.6%; however, these positive cells only expressed 28.6% of the mean fluorescence level of LRP+/+ control cells and, therefore, had only 20% of the level of LRP expression compared with cells from their sibling controls (percentage of positive cells x mean fluorescence relative to sibling controls). The lowest number of LRP-positive macrophages detected in a macLRP–/– preparation was 7.5% with a mean fluorescence relative to control of 34.2%, or 2.6% of the LRP expression of the control cells. Therefore, the range in LRP expression on macLRP–/– BMDM relative to LRP+/+ controls was between 2.6 and 20.4%. Taken together, these results demonstrate an efficient deletion or diminution of LRP from both peritoneally derived and bone marrow-derived murine macrophages and, hence, these macrophages were used to assess the role of LRP in regulating C1q-dependent and -independent phagocytosis of a variety of target particles.
|
To determine whether LRP has the potential to mediate phagocytosis, thioglycollate-elicited peritoneal macrophages from LRP+/+ or macLRP–/– mice were incubated with 1-µm fluorescent beads coated with GST-RAP or GST alone. Cells were washed and phagocytosis of the microparticles was measured by flow cytometry. Similar percentages of LRP+/+ and macLRP–/– macrophages internalized GST-coated beads, with 34.1 ± 4.6% and 32.1 ± 3.8% of cells taking up GST-coated beads, respectively (Fig. 3A). The phagocytic indices for the GST-coated beads were also similar between LRP+/+ and macLRP–/– cells (59.9 ± 20 and 48 ± 10.9, respectively) (Fig. 3B). When cells were incubated with GST-RAP-coated beads, LRP-expressing macrophages exhibited an increase in both the percentage of phagocytosis, from 34.1 ± 4.6% with GST-coated beads to 58.6 ± 2.4% with GST-RAP-coated beads (p = 0.002) (Fig. 3A), and a >3-fold increase in the phagocytic index from 59.9 ± 20.3 to 199.4 ± 24.9, respectively (p = 0.002) (Fig. 3B). In contrast, LRP-deficient cells failed to demonstrate enhanced ingestion of GST-RAP-coated beads compared with GST-coated beads. The percentage of mac-LRP–/– macrophages that ingested GST-RAP-coated beads was equivalent to those ingesting GST-coated beads (27.3 ± 2.1 and 32.1 ± 3.8%, respectively) (Fig. 3A). Likewise, the phagocytic indices for LRP-deficient macrophages ingesting GST-RAP and GST-coated beads were also similar (36.2 ± 5.6 and 48.0 ± 10.9, respectively) (Fig. 3B), demonstrating no response to the presence of RAP on the beads in the absence of LRP.
|
To verify the ability of LRP to mediate phagocytosis of a physiologically relevant ligand, peritoneal macrophages were also incubated with microbeads coated with the HBD derived from thrombospondin fused to GST or, as a control, GST alone. Thrombospondin-1 is an LRP ligand, and the LRP binding site is located within its HBD (32, 33). After incubation, the cells were washed and phagocytosis of the microparticles was measured by microscopy. Anti-GST IgG was used to detect beads that were surface bound but not internalized, and only internalized beads were scored. LRP+/+ and macLRP–/– macrophages internalized similar levels of GST-coated beads, with 70.4 ± 2.0 and 67.2 ± 4.8% of cells taking up GST-coated beads, respectively in this experiment (Fig. 4A). The phagocytic indices for the GST-coated beads were also similar between LRP+/+ and macLRP–/– cells (259.2 ± 94.6 and 252.5 ± 33.6, respectively) (Fig. 4B). When the cells were incubated with GST-HBD-coated beads, LRP-expressing macrophages exhibited an increase in both the percentage of phagocytosis, from 70.3% with GST-coated beads to 83.2% with GST-HBD-coated beads (p = 0.014) (Fig. 4A), and a 1.9-fold increase in the phagocytic index from 259.2 ± 94.6 to 488.6 ± 90.5, respectively (p = 0.0001) (Fig. 4B). In contrast, LRP-deficient cells failed to demonstrate enhanced ingestion of GST-HBD-coated beads compared with GST-coated beads. The percentage of macLRP–/– macrophages that ingested GST-HBD-coated beads was equivalent to those ingesting GST-coated beads (67.2 ± 4.8 and 67.9 ± 12%, respectively) (Fig. 4A). Likewise, the phagocytic indices for LRP-deficient macrophages ingesting GST-HBD and GST-coated beads were also similar (226.9 ± 81 and 252.5 ± 33.6, respectively) (Fig. 4B), demonstrating no response to the presence of HBD on the beads in the absence of LRP. In the same experiment, phagocytosis of GST-RAP-coated beads was also measured and, similar to the results shown in Fig. 3, these data confirmed that the percentage of cells ingesting beads was greater in LRP-expressing cells than in LRP-deficient cells (95.5 ± 7.6 vs 65.5 ± 5.9%, respectively; p = 0.005). Likewise, the phagocytic index of GST-RAP-coated beads was considerably higher in LRP-expressing cells when compared with LRP-deficient cells (607.8 ± 88 vs 288.4 ± 154, respectively; p = 0.03).
|
LRP-deficient macrophages demonstrate C1q-mediated enhanced phagocytosis of EAIgG or EAIgMC4b
Having demonstrated that macrophage LRP participates in the phagocytosis of particles bearing LRP ligands on their surfaces, we sought to determine whether LRP is required to mediate C1q-enhancement of phagocytosis, as previously suggested (34). To test this hypothesis, we isolated BMDM from LRP+/+ and mac-LRP–/– mice and evaluated their ability to engulf sheep RBC suboptimally opsonized with IgG (EAIgG) following adhesion to 4 or 8 µg/ml C1q-coated surfaces or, as a control, human serum albumin (HSA)-coated surfaces. As expected, there was an increase in both the percentage of phagocytosis and the phagocytic index when LRP-expressing cells were adherent to 4 or 8 µg/ml C1q (Fig. 5). Additionally, LRP-deficient macrophages responded to C1q with an enhancement of the percentage of phagocytosis and the phagocytic index comparable to that of LRP+/+ macrophages under all conditions tested (that is, 4 and 8 µg/ml C1q as the coating concentration and using two additional different concentrations of IgG to opsonize the targets; data not shown). For example, at 4 µg/ml HSA, LRP+/+ and macLRP–/– macrophages demonstrated 8.5 ± 1.8 and 14.1 ± 0.9% phagocytosis respectively and this increased to 45.7 ± 0.9 and 42.9 ± 2.3%, respectively, when cells were plated on C1q (Fig. 5A). Only 13% of the macLRP–/– macrophages used in the representative experiment shown in Fig. 5 expressed LRP, and these LRP-expressing macrophages expressed only 15.1% of the mean fluorescence level expressed by control LRP+/+ cells. Because 42.9% of the macLRP–/– macrophages ingested targets in this experiment, these data demonstrate that LRP is not required for the C1q-triggered enhancement of phagocytosis of Ab-opsonized targets.
|
receptors. To determine whether multiple forms of C1q-triggered enhanced phagocytosis were active in the macLRP–/– cells, we compared the ability of macLRP–/– macrophages to engulf sheep RBC opsonized with the complement component C4b (EAIgMC4b). Both LRP+/+ and macLRP–/– macrophages responded to C1q with an enhancement of the percentage of phagocytosis and the phagocytic index of EAC4b, and there was no significant difference between the genotypes (Fig. 6). For example, in the experiment shown in Fig. 6, both LRP+/+ and macLRP–/– macrophages responded to 8 µg/ml C1q with a 3.7-fold enhancement of phagocytosis. In the experiment shown, 43.6 and 44% of macLRP–/– macrophages expressed LRP; however, of the macLRP–/– cells expressing LRP, LRP expression levels were only 16.2–18.3% of LRP+/+ macrophage controls. Therefore, there was a >5-fold reduction in LRP expression on macLRP–/– cells; however, there was no effect on the C1q-triggered enhancement of phagocytosis. These data demonstrate that LRP is not required for the C1q-triggered enhancement of phagocytosis of Ab- or complement-coated particles.
|
To determine whether LRP plays a role in the phagocytosis of apoptotic cells, we examined the phagocytosis of apoptotic Jurkat cells by LRP-expressing and LRP-deficient BMDM under a variety of serum-free or serum-containing conditions. BMDM from LRP+/+ and macLRP–/– mice were incubated with live or apoptotic Jurkat cells at a ratio of three Jurkat cells for every one BMDM for 30 min at 37°C. Cells were stained for CD11b, a common macrophage marker, and analyzed by flow cytometry. Representative dot plots from one of four independent experiments are shown comparing the uptake of Jurkat cells by LRP+/+ and macLRP–/– BMDM (Fig. 7). Only 13% of the macLRP–/– macrophages used in the representative experiment shown expressed LRP, and these LRP-expressing macrophages expressed only 15.1% of the mean fluorescence level expressed by control LRP+/+ cells. In a replicate experiment (not shown), only 7.5% of macLRP–/– cells expressed LRP while 15.5% of cells engulfed apoptotic cells in a C1q- dependent manner (42% phagocytosis for the C1q-deficient serum and 57.5% phagocytosis when reconstituted with C1q). These data demonstrate that LRP is not required for the C1q-dependent or -independent phagocytosis of apoptotic cells under the specified conditions. Results from each of the four experiments performed were averaged and are shown in Fig. 8. No averages are plotted for apoptotic cells phagocytosed in the presence of C1q-deficient serum supplemented with mouse C1q because this condition was used in only one experiment.
|
|
Multiple factors in serum, in addition to C1q and other complement factors, contribute to the efficiency of phagocytosis of apoptotic cells (35). Indeed, we observed a similar increase in the phagocytosis of apoptotic Jurkat cells in the presence of normal mouse serum (NMS) by BMDM from both LRP+/+ and macLRP–/– mice. LRP-expressing and LRP-deficient macrophages exhibited a 4.2- and 4.5-fold increase in the ingestion of apoptotic targets in the presence of serum, respectively, when compared with the serum-free samples (Figs. 7 and 8). These data demonstrate that phagocytosis of apoptotic Jurkat cells in the presence or absence of serum occurs with equal efficiency in LRP+/+ and macLRP–/– macrophages, suggesting that LRP is not required for the ingestion of apoptotic Jurkat cells.
To examine the role of C1q in the serum-mediated increase in phagocytosis, we performed the same phagocytosis assay in the presence of mouse serum genetically devoid of C1q (C1q–/–) (12). When the assay was performed using C1q–/– mouse serum and the results compared with NMS, we observed a 27.2 and 25.9% decrease in the phagocytosis of apoptotic Jurkat cells by LRP+/+ and macLRP–/– BMDM, respectively (Figs. 7 and 8). These results confirm that C1q is one of the factors in NMS that contributes to the serum-induced enhancement of phagocytosis. Furthermore, supplementing the C1q–/– serum with human C1q returned the percentage of phagocytosis values to 98.2 and 101.9% of the values obtained in the presence of NMS in LRP+/+ and macLRP–/– macrophages, respectively (n = 4). Importantly, there were no differences in the percentages of phagocytosis between BMDM from LRP+/+ and macLRP–/– macrophages in any of the conditions tested. These studies verify that C1q is one factor in serum responsible for the increased phagocytosis of apoptotic Jurkat cells by BMDM and that the C1q-mediated enhancement of phagocytosis in complete serum occurs independently of LRP.
| Discussion |
|---|
|
|
|---|
To investigate the potential of LRP to mediate phagocytosis, we examined the ability of LRP-expressing and LRP-deficient macrophages to mediate the phagocytosis of microbeads coated with GST-RAP, GST-HBD, or GST. The finding that GST-RAP and GST-HBD-coated microbeads are more efficiently ingested by LRP-expressing cells provides direct evidence that endogenous LRP contributes to phagocytosis in professional phagocytes. These results are also consistent with hypotheses from past published work. Kinchen et al. reported that a receptor in Caenorhabditis elegans, CED-1, through interaction with the adaptor protein CED-6, initiates the reorganization of actin necessary for phagocytosis (36), and they proposed that, in the mammalian system, LRP could play a similar role as that of CED-1. The human homologue of CED-6, GULP, is an adaptor protein that was shown to interact with phosphorylated forms of the LRP intracellular domain (21, 37). Additionally, the CED-1 homologue in Drosophila, Draper, was shown by others to play a critical role in the phagocytosis of apoptotic cells (38, 39). Finally, it was previously demonstrated that the LRP cytoplasmic domain contains sufficient information to trigger phagocytosis (22). Our studies confirm that LRP has the capacity to mediate phagocytosis of particles bearing LRP ligands on their surfaces.
We next used this genetic model to test the hypothesis that LRP is the receptor responsible for mediating C1q enhancement of phagocytosis in professional phagocytes and/or that LRP is required for the C1q-dependent or -independent uptake of apoptotic cells (6, 18, 34). MacLRP–/– BMDM displayed enhanced ingestion of Ab- and complement-opsonized RBC when adherent to C1q, which was comparable to levels demonstrated by LRP+/+ control macrophages. In addition, apoptotic Jurkat cells were ingested equivalently by LRP+/+ and macLRP–/– macrophages in the presence or absence of serum. Ingestion of Jurkat cells by both LRP-deficient and LRP-expressing macrophages was reduced in the presence of C1q–/– serum compared with NMS; however, ingestion at the NMS level could be reconstituted for both LRP+/+ and macLRP–/– when purified C1q was added back. These studies demonstrate that C1q-enhanced phagocytosis, via multiple physiologically important pathways, can occur independently of LRP, suggesting that other, as of yet unidentified C1q receptors or receptor complexes exist.
The use of suboptimally opsonized erythrocytes coated with either IgG or C4b enabled us to look at C1q enhancement of Fc receptor- and complement-mediated phagocytosis. Previous studies identified a six-amino acid stretch in the collagen-like tail of C1q responsible for triggering the enhanced ingestion (29); however, the phagocyte receptor (or receptor complex) that binds the six-amino acid stretch has remained elusive. Our results unequivocally show that C1q enhances both Fc receptor- and complement-mediated phagocytosis equally well in LRP-deficient and LRP-expressing macrophages, demonstrating that LRP is not a required receptor through which C1q mediates this enhancement. Importantly, previous studies suggesting a required role for LRP in C1q-enhanced ingestion have focused on phagocytosis of apoptotic cells (6, 7, 18, 34), and it is possible that enhanced ingestion of Ab- and complement-opsonized particles following adhesion to C1q-coated surfaces (as demonstrated in Figs. 5 and 6) occurs via an alternative mechanism. In support of this hypothesis, previous studies showed that adhesion to C1q triggers an inhibition rather than an enhancement of uptake of apoptotic cells (34). However, in the present study we show that under serum-free and a variety of serum-containing conditions, apoptotic Jurkat cells were ingested equally well by LRP-expressing and LRP-deficient macrophages, suggesting that LRP is not essential for the phagocytosis of apoptotic cells.
Multiple receptors have been suggested to be involved in the ingestion of apoptotic cells including LRP,
vβ3, CD36, and others (reviewed in Ref. 1). Ogden and colleagues reported that anti-LRP and anti-CRT Abs inhibited human monocyte-derived macrophage phagocytosis of apoptotic Jurkat cells and erythrocytes bearing C1q tails on their surfaces (34). They suggested that C1q, when bound to apoptotic cells, is recognized by CRT on the phagocyte, which signals through LRP to induce phagocytosis. Similarly, Vandivier and colleagues reported that two collectins, the lung surfactant proteins SP-A and SP-D, performed a similar function as that of C1q and enhanced ingestion of apoptotic neutrophils by alveolar macrophages in a CRT/LRP-dependent fashion, again using Abs against CRT and LRP to block function (18). In this study we demonstrate that the presence of C1q in serum enhances the ingestion of apoptotic Jurkat cells by macrophages. As previously shown by other laboratories (40, 41), there was a significant reduction in the phagocytosis of apoptotic cells in the presence of C1q-deficient serum compared with NMS, and a full recovery when C1q-deficient serum was supplemented with purified C1q. It should be noted that, in addition to preventing direct C1q-mediated enhancement of phagocytosis via a C1q receptor, the use of C1q-deficient serum also prevents activation of the classical complement pathway (41). Thus, the enhancement of phagocytosis seen upon adding back purified C1q to serum, which contains other soluble complement factors, could be due to uptake mediated by a C3 activation fragment, C3b or iC3b, via complement receptor types 1 or 3 or other complement receptors (41). Further studies will be required to determine whether purified C1q, in the absence of other complement components, facilitates enhanced ingestion of apoptotic cells with macLRP–/– macrophages.
A second model addressing the role of LRP in the clearance of apoptotic cells was proposed by Gardai and colleagues, suggesting that phagocyte LRP binds CRT on the surface of apoptotic cells and that this interaction is required for phagocytosis (7). This was referred to as the "trans" model because it described the interaction between LRP and CRT on two separate cells and it differentiated this model from the "cis-" model (34), which states that CRT and LRP are both found on the engulfing cell where they function as a complex to bind C1q on the apoptotic cell and mediate phagocytosis. Gardai et al. reported that blocking Abs against CRT reduced the ingestion of apoptotic fibroblasts, neutrophils, and Jurkat cells by fibroblasts (used as engulfing cells) and that apoptotic, CRT-deficient murine embryonic fibroblasts were less efficiently cleared than apoptotic, wild-type murine embryonic fibroblasts from the peritoneum of normal mice, suggesting a role for CRT as a surface ligand important for the removal of apoptotic cells (7). In addition, anti-LRP Abs and treatment with RAP were used to demonstrate a decrease in LRP-mediated phagocytosis of apoptotic neutrophils by the J774 macrophage cell line. The "trans" model would predict that we should observe a decrease in the phagocytosis of apoptotic cells by LRP-deficient macrophages in serum-free conditions (i.e., in the absence of C1q or other serum factors). However, macLRP–/– macrophages consistently ingested comparable numbers of apoptotic cells compared with LRP+/+ macrophages over four repeat experiments. These data indicate that LRP is not essential for the phagocytosis of apoptotic cells and suggest that either redundant pathways of ingestion are available that fully compensate for the loss of LRP or that the "trans" pathway is not the major mechanism for the engulfment of nonopsonized Jurkat cells.
In comparing systems used in previous studies to our results presented here, it should be noted that previous studies used Jurkat cells that were rendered apoptotic by UV irradiation, whereas the studies herein induced apoptosis with etoposide. It is possible that these different methods could lead to a different series of ligands displayed on the surface of apoptotic cells and may account for the discrepancies noted, although no precedence for such a difference was found in a review of the literature. In addition, while Ogden et al. demonstrated that adhesion to C1q-coated surfaces resulted in an inhibition of phagocytosis of apoptotic cells in human monocyte-derived macrophages (presumably by sequestering LRP at the base of the cell) (34), we did not detect an inhibition of the uptake of apoptotic cells with murine BMDM adherent to C1q (data not shown). Similarly, in our experiments (data not shown) the opsonization of apoptotic cells with purified C1q did not reproducibly trigger enhanced ingestion, in contrast to what has been demonstrated in previously published systems (6, 34). Taken together, these data demonstrate that the contribution of LRP to C1q-dependent and -independent enhancement of phagocytosis of apoptotic cells appears to be highly dependent on the specific myeloid cell type and/or apoptotic cell system used. Nevertheless, our data definitively reveal a system in which the engulfment of apoptotic cells is independent of LRP and the enhancement of phagocytosis by C1q, in the context of whole serum or purified C1q immobilized on plastic, is also independent of LRP.
Finally, verifying that a given protein mediates a specific function in an in vitro cell-based system is difficult when using Abs or inhibitors alone. As mentioned in the Introduction, identification of the C1q receptor that mediates the enhanced ingestion of Ab- and complement-opsonized targets, which may or may not be the same receptor that mediates the engulfment of C1q-opsonized apoptotic cells, has proven elusive. CD93 was suggested to mediate the C1q-triggered enhancement of phagocytosis based on compelling in vitro Ab studies and other indirect means of testing function (for a full discussion the reader is referred to Ref. 2); but when CD93–/– mice were generated, in vitro studies showed similar C1q-mediated enhancement between CD93–/– and control macrophages (17). The LRP-deficient macrophages used in this study offered a similar opportunity to test proposed roles for LRP, and future studies using the mice will enable verification of these conclusions in vivo. It is possible that blocking Abs and/or soluble RAP, which were used in previous experiments to suggest a nonredundant role for LRP and CRT in the engulfment of apoptotic cells, are generating inhibitory signals resulting in diminished phagocytosis. Further experimentation using these reagents in conjunction with macLRP–/– macrophages should help clarify the mechanism by which these receptors modulate phagocytosis. It is also possible that both CD93 and LRP are involved in this function and that one receptor compensates in the absence of the other. Generation of double-deficient macrophages (LRP–/–/CD93–/–) can be used to address this possibility.
In summary, results using murine macrophages genetically deficient in LRP demonstrate that: 1) LRP is capable of contributing to the phagocytosis of targets bearing LRP ligands on their surfaces; 2) LRP is not required for C1q-triggered enhancement of phagocytosis of IgG- or C4b-opsonized particles and, as such, is not the C1q receptor used in this system; and 3) LRP is not required for phagocytosis of apoptotic cells in vitro either directly (in the absence of serum) or by C1q-mediated effects in the presence of complete serum. Despite our conclusions based on the evidence reported here, previously published work suggests that LRP has the potential to mediate the phagocytosis of apoptotic cells in other cellular systems (e.g., fibroblasts) (6, 7, 18, 21, 34). Future experiments using the macLRP–/– mice should enable the identification of specific systems in or conditions under which LRP is involved in the uptake of apoptotic cells and/or other physiologically relevant, LRP-dependent, phagocytic targets.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by the Duke University Medical Scientist Training Program, Grant T32 GM007171 from the National Institute of General Medical Sciences (to A.P.L.), T32 HL007698 (to A.P.L.), and National Institutes of Health Grants HL-24066 (to S.V.P.), AI-41090 (to A.J.T.), HL054710 (to D.K.S.), HL050784 (to D.K.S.) and AHA 0630068N (to S.S.B.). ![]()
2 Address correspondence and reprint requests to Dr. Suzanne S. Bohlson, Indiana University School of Medicine, 1234 Notre Dame Avenue, South Bend, IN 46617. ![]()
3 Abbreviations used in this paper: LRP, low-density lipoprotein receptor-related protein 1; BMDM, bone marrow-derived macrophage; CRT, calreticulin; EAIgG, sheep erythrocytes opsonized with IgG; EAIgMC4b, sheep erythrocytes opsonized with complement component C4b; HBD, heparin binding domain; HSA, human serum albumin; macLRP, LRP-deficient macrophages; NMS, normal mouse serum; RAP, receptor-associated protein. ![]()
Received for publication July 30, 2007. Accepted for publication April 26, 2008.
| References |
|---|
|
|
|---|
or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 115: 13-23. [Medline]
2-macroglobulin receptor/low density lipoprotein receptor-related protein: multiple regulatory sites for 39-kDa receptor-associated protein. J. Biol. Chem. 267: 9035-9040.
2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J. Biol. Chem. 265: 17401-17404.
2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin: a process facilitated by cell-surface proteoglycans. J. Biol. Chem. 270: 9543-9549.
regulates endocytosis and association with adaptor molecules. J. Biol. Chem. 279: 40536-40544. This article has been cited by other articles:
![]() |
Y. Chen, S. Khanna, C. S. Goodyear, Y. B. Park, E. Raz, S. Thiel, C. Gronwall, J. Vas, D. L. Boyle, M. Corr, et al. Regulation of Dendritic Cells and Macrophages by an Anti-Apoptotic Cell Natural Antibody that Suppresses TLR Responses and Inhibits Inflammatory Arthritis J. Immunol., July 15, 2009; 183(2): 1346 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, Y.-B. Park, E. Patel, and G. J. Silverman IgM Antibodies to Apoptosis-Associated Determinants Recruit C1q and Enhance Dendritic Cell Phagocytosis of Apoptotic Cells J. Immunol., May 15, 2009; 182(10): 6031 - 6043. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zhang, J. An, D. K. Strickland, and M. Yepes The Low-Density Lipoprotein Receptor-Related Protein 1 Mediates Tissue-Type Plasminogen Activator-Induced Microglial Activation in the Ischemic Brain Am. J. Pathol., February 1, 2009; 174(2): 586 - 594. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |